Timothy Hatlen to Humans
This is a "connection" page, showing publications Timothy Hatlen has written about Humans.
Connection Strength
0.541
-
Staphylococcal Skin and Soft Tissue Infections. Infect Dis Clin North Am. 2021 03; 35(1):81-105.
Score: 0.070
-
Oral fosfomycin use for pyelonephritis and complicated urinary tract infections: a 1 year review of outcomes and prescribing habits in a large municipal healthcare system. J Antimicrob Chemother. 2020 07 01; 75(7):1993-1997.
Score: 0.068
-
Necrotic ulcer on the thigh. Cutis. 2017 Aug; 100(2):80;91.
Score: 0.056
-
Nonprogrammable and programmable cerebrospinal fluid shunt valves: a 5-year study. J Neurosurg Pediatr. 2012 May; 9(5):462-7.
Score: 0.039
-
Contributory factors to postoperative spinal fusion complications for children with myelomeningocele. Spine (Phila Pa 1976). 2010 Jun 01; 35(13):1294-9.
Score: 0.034
-
Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment. PLoS One. 2025; 20(6):e0325561.
Score: 0.024
-
No evidence of a detrimental effect of pitavastatin on neurocognitive function among people with HIV. AIDS. 2025 Nov 01; 39(13):1913-1919.
Score: 0.024
-
SARS-Cov-2 vaccination strategies in hospitalized recovered COVID-19 patients: a randomized clinical trial (VATICO Trial). Sci Rep. 2025 Mar 22; 15(1):9882.
Score: 0.024
-
Evaluation of the Feasibility and Efficacy of Point-of-Care Antibody Tests for Biomarker-Guided Management of Coronavirus Disease 2019. J Infect Dis. 2025 Mar 17; 231(3):677-683.
Score: 0.024
-
HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine Nonresponse: The BEe-HIVe Randomized Clinical Trial. JAMA. 2025 01 28; 333(4):295-306.
Score: 0.023
-
Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study. Lancet Microbe. 2024 06; 5(6):e559-e569.
Score: 0.022
-
Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19. J Infect Dis. 2024 03 14; 229(3):671-679.
Score: 0.022
-
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials. JAMA Netw Open. 2023 07 03; 6(7):e2323349.
Score: 0.021
-
A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR). Eur Respir J. 2023 02; 61(2).
Score: 0.020
-
Lessons from an international trial evaluating vaccination strategies for recovered inpatients with COVID-19 (VATICO). Med. 2022 08 12; 3(8):531-537.
Score: 0.020
-
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial. Ann Intern Med. 2022 09; 175(9):1266-1274.
Score: 0.020
-
A nurse-led intervention to improve management of virological failure in public sector HIV clinics in Durban, South Africa: A pre- and post-implementation evaluation. S Afr Med J. 2021 Mar 31; 111(4):299-303.
Score: 0.018
-
High-Dose Fluconazole Consolidation Therapy for Cryptococcal Meningitis in Sub-Saharan Africa: Much to Gain, Little to Lose. AIDS Res Hum Retroviruses. 2018 05; 34(5):399-403.
Score: 0.014